SCHEMBL5469877

SCHEMBL5469877

CCCC[N+]1([O-])CCCC1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1527590 0.97 CYP1A2 (0.31)
SCHEMBL11260353 0.92 TSHR (0.33) TSHR
SCHEMBL15572200 0.90 TSHR (0.38) LMNATSHR
SCHEMBL8590656 0.90 TSHR (0.32) TSHR
SCHEMBL6673774 0.90 TSHR (0.38) LMNATSHR
SCHEMBL1258373 0.90 TSHR (0.38) LMNATSHR
SCHEMBL8026449 0.88 TSHR (0.36) LMNATSHR
SCHEMBL50152 0.88 TSHR (0.36) LMNATSHR
SCHEMBL7398423 0.88 TSHR (0.36) LMNATSHR
SCHEMBL9876888 0.87 TSHR (0.33) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4188585-B1 METHOD OF PRODUCING CARBON MOLECULAR SIEVE MEMBRANES DOW GLOBAL TECHNOLOGIES LLC (US) 2025-11-19 EP claimed
US-12472482-B2 Method of producing carbon molecular sieve membranes DOW GLOBAL TECHNOLOGIES LLC (US) 2025-11-18 US claimed
US-20230278006-A1 METHOD OF PRODUCING CARBON MOLECULAR SIEVE MEMBRANES DOW GLOBAL TECHNOLOGIES LLC (US) 2023-09-07 US claimed
EP-4188585-A1 METHOD OF PRODUCING CARBON MOLECULAR SIEVE MEMBRANES Dow Global Technologies LLC (US) 2023-06-07 EP claimed
WO-2022026136-A1 METHOD OF PRODUCING CARBON MOLECULAR SIEVE MEMBRANES DOW GLOBAL TECHNOLOGIES LLC (US) 2022-02-03 WO claimed
WO-2014179673-A1 PROCESSES FOR PURIFYING A CELLULOSIC MATERIAL CELANESE INTERNATIONAL CORPORATION (US) 2014-11-06 WO claimed
US-20140326421-A1 Processes for Purifying a Cellulosic Material CELANESE INTERNATIONAL CORPORATION (US) 2014-11-06 US claimed
US-8632816-B2 Compositions comprising solid particles entrapped in collapsed polymeric microspheres, and methods of making the same ELC MANAGEMENT, LLC (US) 2014-01-21 US claimed
US-20130071453-A1 Compositions Comprising Solid Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same ELC MANAGEMENT LLC 2013-03-21 US claimed
EP-4188585-B1 METHOD OF PRODUCING CARBON MOLECULAR SIEVE MEMBRANES DOW GLOBAL TECHNOLOGIES LLC (US) 2025-11-19 EP disclosed
US-12472482-B2 Method of producing carbon molecular sieve membranes DOW GLOBAL TECHNOLOGIES LLC (US) 2025-11-18 US disclosed
US-20230278006-A1 METHOD OF PRODUCING CARBON MOLECULAR SIEVE MEMBRANES DOW GLOBAL TECHNOLOGIES LLC (US) 2023-09-07 US disclosed
US-20230167545-A1 STABILIZATION OF CARBON DEPOSITION PRECURSORS LIKE C2H2 LAM RESEARCH CORPORATION 2023-06-01 US disclosed
CN-115989077-A Solution of sulfone polymer in N-tert-butyl-2-pyrrolidone for membranes 巴斯夫欧洲公司 2023-04-18 CN disclosed
WO-2014179673-A1 PROCESSES FOR PURIFYING A CELLULOSIC MATERIAL CELANESE INTERNATIONAL CORPORATION (US) 2014-11-06 WO disclosed
WO-2014031667-A1 METHODS FOR REMOVING HEMICELLULOSE CELANESE INTERNATIONAL CORPORATION (US) 2014-02-27 WO disclosed
US-8632816-B2 Compositions comprising solid particles entrapped in collapsed polymeric microspheres, and methods of making the same ELC MANAGEMENT, LLC (US) 2014-01-21 US disclosed
US-20130071453-A1 Compositions Comprising Solid Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same ELC MANAGEMENT LLC 2013-03-21 US disclosed
US-20070293538-A1 Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders MYRIAD GENETICS, INCORPORATED (US) 2007-12-20 US disclosed
WO-2006001877-A2 COMBINATION TREATMENT FOR NEURODEGENERATIVE DISORDERS COMPRISING R-FLURBIPROFEN MYRIAD GENETICS, INC. (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293538-A1 Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders GRN, NLN, PSEN1 LMNA 1156/4885TSHR 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.